Subtopic Deep Dive
Sudden Cardiac Death Risk Stratification
Research Guide
What is Sudden Cardiac Death Risk Stratification?
Sudden Cardiac Death Risk Stratification develops scoring systems integrating ECG, imaging, genetics, and family history to predict SCD in cardiomyopathy patients.
Researchers validate models like HCM Risk-SCD in prospective cohorts for hypertrophic cardiomyopathy (HCM). Key papers include O’Mahony et al. (2013) with 1169 citations introducing HCM Risk-SCD, and Chan et al. (2014) with 1006 citations on contrast-enhanced CMR for SCD risk. Over 10 high-citation papers from 1995-2017 focus on HCM and athlete sudden deaths.
Why It Matters
Risk stratification identifies high-risk HCM patients for ICD implantation, preventing fatal arrhythmias in young athletes and general populations. O’Mahony et al. (2013) provide validated models using clinical parameters for individualized SCD probability estimates. Chan et al. (2014) show quantitative CMR identifies patients eligible for SCD prevention not captured by traditional factors. Elliott et al. (2014) guidelines integrate these for HCM management, reducing sudden deaths reported in Maron et al. (2009).
Key Research Challenges
Model Validation in Cohorts
Prospective validation of risk scores like HCM Risk-SCD remains limited to specific populations. O’Mahony et al. (2013) validated in HCM cohorts but generalizability to diverse cardiomyopathies is unproven. Larger multi-ethnic studies are needed.
Integrating Multimodal Data
Combining ECG, genetics, imaging, and family history into unified scores faces data heterogeneity. Chan et al. (2014) highlight CMR's prognostic value but integration with genetic testing from Ackerman et al. (2011) lacks standardized models. Computational challenges persist.
Genetic Risk Prediction Accuracy
Genetic testing for channelopathies and cardiomyopathies shows variable SCD predictive power. Ackerman et al. (2011) consensus notes limitations in routine use for risk stratification. Seidman and Seidman (2001) identify genetic basis but clinical translation to scores is incomplete.
Essential Papers
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Perry Elliott, Aris Anastasakis, Michael A. Borger et al. · 2014 · European Heart Journal · 4.2K citations
NOT AVAILABLE
Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults
Barry J. Maron, Julius M. Gardin, John M. Flack et al. · 1995 · Circulation · 2.2K citations
Background Hypertrophic cardiomyopathy (HCM) is a genetically transmitted disease and an important cause of morbidity and sudden cardiac death in young people, including competitive athletes. At pr...
Sudden Deaths in Young Competitive Athletes
Barry J. Maron, Joseph J. Doerer, Tammy S. Haas et al. · 2009 · Circulation · 2.0K citations
Background— Sudden deaths in young competitive athletes are highly visible events with substantial impact on the physician and lay communities. However, the magnitude of this public health issue ha...
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
Michael J. Ackerman, Silvia G. Priori, Stephan Willems et al. · 2011 · Heart Rhythm · 1.4K citations
Sudden Death in Young Athletes
Barry J. Maron · 2003 · New England Journal of Medicine · 1.4K citations
This article summarizes the available information regarding the cardiac risks of participation in athletics. Hypertrophic cardiomyopathy remains the leading cause of sudden death from cardiac cause...
Hypertrophic Cardiomyopathy
Ali J. Marian, Eugene Braunwald · 2017 · Circulation Research · 1.3K citations
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or incre...
A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)
Constantinos O’Mahony, Fatima Jichi, Menelaos Pavlou et al. · 2013 · European Heart Journal · 1.2K citations
This is the first validated SCD risk prediction model for patients with HCM and provides accurate individualized estimates for the probability of SCD using readily collected clinical parameters.
Reading Guide
Foundational Papers
Start with Elliott et al. (2014, 4217 citations) for ESC HCM guidelines integrating risk factors. Follow with O’Mahony et al. (2013, 1169 citations) for first validated HCM Risk-SCD model. Maron et al. (1995, 2234 citations) establishes HCM prevalence and SCD link.
Recent Advances
Chan et al. (2014, 1006 citations) on CMR for SCD risk. Marian and Braunwald (2017, 1265 citations) reviews HCM genetics and hypertrophy. Ackerman et al. (2011, 1448 citations) on genetic testing consensus.
Core Methods
HCM Risk-SCD scoring (O’Mahony 2013): age, thickness, outflow obstruction, syncope, family history, NSVT. Quantitative CMR fibrosis volume (Chan 2014). Genetic panels for channelopathies/cardiomyopathies (Ackerman 2011).
How PapersFlow Helps You Research Sudden Cardiac Death Risk Stratification
Discover & Search
Research Agent uses searchPapers and citationGraph to map 250M+ papers, starting from O’Mahony et al. (2013) HCM Risk-SCD to find 50+ citing works on SCD models. exaSearch uncovers cohort studies beyond OpenAlex; findSimilarPapers links Chan et al. (2014) CMR to imaging risk papers.
Analyze & Verify
Analysis Agent applies readPaperContent to extract risk factors from Elliott et al. (2014) guidelines, then verifyResponse with CoVe chain-of-verification checks model accuracies against cohorts. runPythonAnalysis reimplements HCM Risk-SCD scoring in pandas sandbox with GRADE grading for evidence strength; statistical verification tests CMR thresholds from Chan et al. (2014).
Synthesize & Write
Synthesis Agent detects gaps in genetic-imaging integration from Ackerman et al. (2011) and Seidman papers, flagging contradictions in athlete SCD rates from Maron et al. (2009). Writing Agent uses latexEditText, latexSyncCitations for risk model reviews, latexCompile for figures, and exportMermaid for stratification flowcharts.
Use Cases
"Reproduce HCM Risk-SCD calculator from O’Mahony 2013 with sample patient data"
Research Agent → searchPapers(O’Mahony) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas model implementation, matplotlib ROC curves) → outputs interactive calculator and validation stats.
"Draft LaTeX review of SCD risk models in HCM guidelines"
Synthesis Agent → gap detection(Elliott 2014 vs O’Mahony) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → outputs compiled PDF with risk table.
"Find code for CMR analysis in Chan 2014 sudden death risk"
Research Agent → paperExtractUrls(Chan) → paperFindGithubRepo(CMR quantification) → githubRepoInspect → outputs Python scripts for LGE volume analysis linked to SCD prediction.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ HCM SCD papers: searchPapers → citationGraph → DeepScan(7-step analysis with GRADE checkpoints) → structured report on model comparisons. Theorizer generates hypotheses on myosin genetics in risk from Seidman (2001) via literature synthesis. DeepScan verifies cohort prevalences from Maron (1995) with CoVe and Python stats.
Frequently Asked Questions
What is Sudden Cardiac Death Risk Stratification?
It develops scoring systems integrating ECG, imaging, genetics, and family history to predict SCD in cardiomyopathy patients, validated in prospective cohorts.
What are key methods used?
HCM Risk-SCD by O’Mahony et al. (2013) uses clinical parameters for individualized SCD probability. Quantitative contrast-enhanced CMR by Chan et al. (2014) evaluates fibrosis for risk.
What are key papers?
O’Mahony et al. (2013, 1169 citations) introduced HCM Risk-SCD. Chan et al. (2014, 1006 citations) validated CMR for SCD risk. Elliott et al. (2014, 4217 citations) provide ESC guidelines.
What are open problems?
Generalizing models to diverse populations beyond HCM cohorts. Integrating genetics from Ackerman et al. (2011) with imaging for unified scores. Prospective validation in non-athlete groups.
Research Cardiomyopathy and Myosin Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sudden Cardiac Death Risk Stratification with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cardiomyopathy and Myosin Studies Research Guide